These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11501195)

  • 21. Substitution for protease inhibitors in HIV therapy.
    Mikhail E
    N Engl J Med; 2003 Dec; 349(25):2460-1; author reply 2460-1. PubMed ID: 14689602
    [No Abstract]   [Full Text] [Related]  

  • 22. Mitochondrial toxicity: myths and facts.
    Moyle G
    J HIV Ther; 2004 May; 9(2):45-7. PubMed ID: 15238876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lactic acidosis in HIV patients receiving highly active antiretroviral therapy.
    Chow YW; Leong CL; Chow HL; Hooi LS
    Med J Malaysia; 2007 Mar; 62(1):78-80. PubMed ID: 17682581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.
    Nolan D; John M; Mallal S
    Antivir Ther; 2001 Sep; 6(3):145-60. PubMed ID: 11808750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NRTI induced mitochondrial toxicity as a mechanism for HAART related lipodystrophy: fact or fiction?
    Walker UA; Brinkman K
    HIV Med; 2001 Jul; 2(3):163-5. PubMed ID: 11737396
    [No Abstract]   [Full Text] [Related]  

  • 26. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin.
    Moreno A; Quereda C; Moreno L; Perez-Elías MJ; Muriel A; Casado JL; Antela A; Dronda F; Navas E; Bárcena R; Moreno S
    Antivir Ther; 2004 Feb; 9(1):133-8. PubMed ID: 15040545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lactic acidosis in an HIV-infected patient receiving highly active antiretroviral therapy.
    Patel V; Hedayati SS
    Nat Clin Pract Nephrol; 2006 Feb; 2(2):109-14; quiz 115. PubMed ID: 16932402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of treatment-induced lipid abnormalities and lipodystrophy.
    Smith D
    J HIV Ther; 2001 May; 6(2):25-7. PubMed ID: 11501199
    [No Abstract]   [Full Text] [Related]  

  • 29. Mitochondrial toxicity and lactic acidosis.
    Proj Inf Perspect; 2000 Mar; (29):10-1. PubMed ID: 12772662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiretroviral nucleoside and nucleotide analogues and mitochondria.
    Cossarizza A; Moyle G
    AIDS; 2004 Jan; 18(2):137-51. PubMed ID: 15075530
    [No Abstract]   [Full Text] [Related]  

  • 31. The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells.
    Sternfeld T; Schmid M; Tischleder A; Mudra S; Schlamp A; Kost BP; Gruber R; Youle M; Bogner JR; Goebel FD
    Antivir Ther; 2007; 12(5):769-78. PubMed ID: 17713160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-nucleoside-reverse-transcriptase-inhibitor-based HAART and osteoporosis in HIV-infected subjects.
    Bongiovanni M; Fausto A; Cicconi P; Aliprandi A; Cornalba G; Bini T; Sardanelli F; D'Arminio Monforte A
    J Antimicrob Chemother; 2006 Aug; 58(2):485-6. PubMed ID: 16751202
    [No Abstract]   [Full Text] [Related]  

  • 33. Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy.
    Nelson M; Azwa A; Sokwala A; Harania RS; Stebbing J
    AIDS; 2008 Jul; 22(11):1374-6. PubMed ID: 18580619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome.
    Nolan D; Mallal S
    J HIV Ther; 2004 May; 9(2):34-40. PubMed ID: 15238874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Symptomatic hyperlactataemia and lactic acidosis in the era of highly active antiretroviral therapy.
    Eshun-Wilson I; Soentjens P; Zeier M; Taljaard J
    S Afr Med J; 2005 Dec; 95(12):929-30. PubMed ID: 16465351
    [No Abstract]   [Full Text] [Related]  

  • 36. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.
    Côté HC; Magil AB; Harris M; Scarth BJ; Gadawski I; Wang N; Yu E; Yip B; Zalunardo N; Werb R; Hogg R; Harrigan PR; Montaner JS
    Antivir Ther; 2006; 11(1):79-86. PubMed ID: 16518963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toxicity profile of HAART.
    TreatmentUpdate; 2001; 13(7):6-7. PubMed ID: 11794864
    [No Abstract]   [Full Text] [Related]  

  • 38. Managing issues related to antiretroviral therapy.
    Lesho EP; Gey DC
    Am Fam Physician; 2003 Aug; 68(4):675-86. PubMed ID: 12952384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature.
    Falcó V; Rodríguez D; Ribera E; Martínez E; Miró JM; Domingo P; Diazaraque R; Arribas JR; González-García JJ; Montero F; Sánchez L; Pahissa A
    Clin Infect Dis; 2002 Mar; 34(6):838-46. PubMed ID: 11850865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stavudine in antiretroviral therapy: is this the end?
    Brinkman K
    AIDS; 2009 Aug; 23(13):1727-9. PubMed ID: 19571724
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.